Skip to content
In primary membranous nephropathy, obinutuzumab increased the likelihood of complete remission vs. tacrolimus at 104 wk
All contributors

Onconephrology contributor

Kumada, Hiromitsu

Primarily Anti-VEGF / TKI renal effects#37 of 46 recognized
  • #5 in Anti-VEGF / TKI renal effects
4
Clinical papers
644
Citations (iCite)
0 / 4
First / senior author
2016–2023
Active years

Output over time

Clinical corpus papers per year — peak 1 in 2016, 2017, 2020, 2023.

  • 2016: 1 paper
  • 2017: 1 paper
  • 2020: 1 paper
  • 2023: 1 paper
20162023

Subfield mix

Clinical papers by onconephrology subfield (a paper can count in more than one).

Anti-VEGF / TKI renal effects4

Agents they study

Catalog agents whose clinical kidney literature lists Kumada among the leading contributors (clinical-paper count on that agent).

Lenvatinib3

Verify

Representative recent papers, and this author’s full PubMed bibliography.

PMID 37854758 (opens PubMed in a new tab)PMID 31720835 (opens PubMed in a new tab)PMID 27704266 (opens PubMed in a new tab)PMID 26500236 (opens PubMed in a new tab)All papers on PubMed

A code-tallied bibliometric profile from PubMed + NIH iCite, restricted to human/clinical papers across a 15,541-article corpus (regenerated 2026-10-02). Recognition of published contribution — not a verdict on merit or influence, and not medical advice.